Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

Developing healthier lives for the world


For more information contact us today

Viktoriya Tamlenova-Montano,

Vice President of Strategic Innovation

Viktoriya Tamlenova-Montano served as a director of CardioVascular BioTherapeutics Inc., from August 2012 until the end of 2014. She has a Bachelor’s degree in heavy industry detailing and construction from Kiev College of Electric Engineering and a Bachelor degree in Construction and Industrial Design from Kiev State University of Civil Engineering and Architecture. She also has a Master’s degree in Architecture from Kiev State University of Civil Engineering and Architecture. She is fluent in several languages and acted as interpreter for the first President of Ukraine. She became involved in biotechnology and acted as an advisor and researcher for several biotech companies since 1998. She has an ability "to think outside of the box". She has given seminars at Universities on the new area of biotechnology - epigenetics. At the company, she will be focused upon the area of diabetes, molecular imaging and epigenetics. 

Management Team

Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

Judy Luell, Corporate Secretary
Judy Luell served as corporate secretary for CardioVascular BioTherapeutics and has a broad knowledge of the administrative side of running a biotechnology corporation. She has also assisted in the filing of numerous documents and IND applications to regulatory authorities.

Our Support Staff

Jack Jacobs, Ph.D.,

President and Chief Scientific Officer
Dr. Jacobs received his BS degree from Davidson College and a Ph.D. in molecular biology from Washington University, St. Louis. He has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of Biological Chemistry at Merck and for 15 years worked with Mr. Montano as CardioVascular BioTherapeutics’ Chief Scientific Officer where he oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies.

Ernest Montano,

Vice President of Asia Operations

Ernest Montano was a founding shareholder of CardioVascular BioTherapeutics Inc. (CVBT) in 1998. He led the operations of CVBT in Asia and became a member of the Board
ofdirector in 2012. In 2014, he was one of the founders of Zhittya Regenerative Medicine and now oversees the business development activities for China, Southeast Asia, India, Korea, Japan and Australia/New Zealand.

Daniel Montano

Chief Executive Officer (CEO) and Chairman of the Board

Mr. Montano has a BS degree in Business and Accounting and an MBA degree in Finance from the University of Southern California (USC).
From 1968 until 1998, he was an investment banker in California, managing new start-ups, private placements, IPO’s, corporate turnarounds and acquisitions. Mr. Montano was involved in the starting and handling of the IPOs of over 100 companies during his 30 years as an investment banker. While an investment banker, Mr. Montano, developed and managed over 3,000 retail stockbrokers. During a 30-year period, Mr. Montano raised from investors over $2 billion USD. As part of Mr. Montano’s expertise in managing turnarounds, he was CEO of over 17 publicly-traded companies.

Mr. Montano has also served as a professor at several US universities and as an international speaker on the topics of finance, economics, and business, gave presentations in over 33 nations and advising presidents and prime ministers of several nations. Mr. Montano was a special advisor to President
Krafchuk of Ukraine, to assist in the Ukraine transformation to free market economics from communism.

In 1998, Mr. Montano started a new company called “CardioVascular BioTherapeutics Inc., to develop a biological drug which triggers the growth of new blood vessels in the human heart. As Chairman of the Board, CEO and President of that company, Mr. Montano raised jointly over $130 million USD and created a company, which after its initial public offering (IPO), had a market capitalization of over $1.8 billion USD. During the 2007- 2010 financial crisis, Mr. Montano provided in investment, advances, loans and loan guarantees, over $27 million USD to CardioVascular BioTherapeutics Inc., to attempt to advance the company. In 2010, the contract manufacturer for CardioVascular BioTherapeutics filed for Bankruptcy and forced him to turn to a new direction to advance the drugs.

In 2014, Dan Montano started Zhittya Regenerative Medicine to continue his efforts to bring these life-saving drugs through the USA FDA approval process.